Etoposide
- Generic Name
- Etoposide
- Brand Names
- Etopophos, Toposar, Vepesid
- Drug Type
- Small Molecule
- Chemical Formula
- C29H32O13
- CAS Number
- 33419-42-0
- Unique Ingredient Identifier
- 6PLQ3CP4P3
- Background
A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
- Indication
For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer
- Associated Therapies
- -
High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2006-07-10
- Last Posted Date
- 2017-12-12
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 102
- Registration Number
- NCT00349778
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT
- Conditions
- LeukemiaHematologic DiseasesLymphoma, Non-HodgkinAcute GVHD
- Interventions
- First Posted Date
- 2006-07-10
- Last Posted Date
- 2021-09-23
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 11
- Registration Number
- NCT00350181
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
- Conditions
- Lymphoma
- Interventions
- Drug: cyclophosphamideDrug: carmustineProcedure: peripheral blood stem cell transplantationRadiation: irradiation therapyDrug: etoposideBiological: G-CSFDrug: Cytarabine
- First Posted Date
- 2006-06-29
- Last Posted Date
- 2020-07-14
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 473
- Registration Number
- NCT00345865
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma
- Conditions
- MedulloblastomaAnaplastic MedulloblastomaSupratentorial Embryonal Tumor, Not Otherwise SpecifiedUntreated Childhood Supratentorial Primitive Neuroectodermal Tumor
- Interventions
- Procedure: Autologous Hematopoietic Stem Cell TransplantationDrug: CarboplatinDrug: CisplatinDrug: CyclophosphamideDrug: EtoposideBiological: FilgrastimOther: Laboratory Biomarker AnalysisOther: Quality-of-Life AssessmentDrug: Leucovorin CalciumDrug: ThiotepaDrug: MethotrexateDrug: Vincristine Sulfate
- First Posted Date
- 2006-06-12
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 91
- Registration Number
- NCT00336024
- Locations
- 🇺🇸
Tulane University School of Medicine, New Orleans, Louisiana, United States
🇺🇸Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States
🇺🇸NYU Langone Hospital - Long Island, Mineola, New York, United States
Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma
- Conditions
- Intraocular Retinoblastoma
- Interventions
- First Posted Date
- 2006-06-12
- Last Posted Date
- 2021-02-18
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 331
- Registration Number
- NCT00335738
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Rainbow Babies and Childrens Hospital, Cleveland, Ohio, United States
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States
Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors
- Conditions
- Clear Cell Renal Cell CarcinomaChildhood Renal Cell CarcinomaClear Cell Sarcoma of the KidneyPapillary Renal Cell CarcinomaStage I Renal Cell CancerStage II Renal Cell CancerRhabdoid Tumor of the KidneyStage I Renal Wilms TumorStage IV Renal Wilms TumorStage II Renal Wilms Tumor
- Interventions
- Drug: Doxorubicin HydrochlorideProcedure: Conventional SurgeryDrug: Irinotecan HydrochlorideBiological: DactinomycinDrug: CyclophosphamideDrug: EtoposideDrug: CarboplatinDrug: Vincristine SulfateOther: Laboratory Biomarker AnalysisRadiation: Radiation Therapy
- First Posted Date
- 2006-06-12
- Last Posted Date
- 2017-07-21
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 291
- Registration Number
- NCT00335556
- Locations
- 🇺🇸
Eastern Maine Medical Center, Bangor, Maine, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸Advocate Children's Hospital-Oak Lawn, Oak Lawn, Illinois, United States
Combination Chemotherapy With or Without Topotecan in Treating Patients With Newly Diagnosed Localized Ewing's Sarcoma
- Conditions
- Sarcoma
- Interventions
- Drug: cyclophosphamideDrug: dexrazoxane hydrochlorideDrug: doxorubicin hydrochlorideDrug: etoposideDrug: ifosfamideDrug: vincristine sulfateDrug: topotecan hydrochlorideProcedure: conventional surgeryProcedure: radiation therapy
- First Posted Date
- 2006-06-08
- Last Posted Date
- 2013-06-28
- Lead Sponsor
- Children's Oncology Group
- Registration Number
- NCT00334867
Combination Chemotherapy Followed By Donor Stem Cell Transplant in Treating Patients With Hemophagocytic Lymphohistiocytosis
- Conditions
- Nonneoplastic Condition
- First Posted Date
- 2006-06-08
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- Children's Cancer and Leukaemia Group
- Target Recruit Count
- 288
- Registration Number
- NCT00334672
- Locations
- 🇬🇧
Birmingham Children's Hospital, Birmingham, England, United Kingdom
🇬🇧Watford General Hospital, Herts, England, United Kingdom
🇬🇧Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom
Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
- Conditions
- Lung AdenocarcinomaLung Large Cell CarcinomaLung Squamous Cell CarcinomaMinimally Invasive Lung AdenocarcinomaStage IIIA Lung Non-Small Cell Cancer AJCC v7Stage IIIB Lung Non-Small Cell Cancer AJCC v7Lung Adenosquamous Carcinoma
- Interventions
- First Posted Date
- 2006-06-08
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 29
- Registration Number
- NCT00334815
- Locations
- 🇺🇸
Ballad Health Cancer Care - Norton, Norton, Virginia, United States
🇺🇸Providence Hospital, Mobile, Alabama, United States
🇺🇸Saint Bernards Regional Medical Center, Jonesboro, Arkansas, United States
Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment
- Conditions
- Lymphoma, Non-HodgkinAdvanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma
- Interventions
- First Posted Date
- 2006-05-11
- Last Posted Date
- 2021-07-22
- Lead Sponsor
- British Columbia Cancer Agency
- Target Recruit Count
- 150
- Registration Number
- NCT00324467
- Locations
- 🇨🇦
BC Cancer Agency, Vancouver, British Columbia, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.